Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase III results reported for ertugliflozin in addition to metformin and sitagliptin for diabetes

Sep. 16, 2016

Promising immunotherapy for type 1 diabetes tested in phase I study

Sep. 16, 2016

BioChaperone Combo reduces postprandial glucose and hyperglycemia risk in type 1 diabetes

Sep. 14, 2016

Dual GLP-1R/glucagon receptor agonist MOD-6031 enters phase I development for obesity

Sep. 14, 2016

Ligand Pharmaceuticals initiates phase II study of LGD-6972

Sep. 14, 2016

Semma Therapeutics receives grant for personalized cell therapy for diabetes

Sep. 14, 2016

REDUCE-IT study of Amarin's Vascepa to continue as planned

Sep. 14, 2016

Brain penetration, effects on disease seen with SBC-103 in mucopolysaccharidosis IIIB

Sep. 13, 2016

PNPLA4 identified as novel causative gene for mitochondrial respiratory chain disorders

Sep. 13, 2016

Mutations in PRODH2 could be genetic cause of hydroxyprolinemia

Sep. 13, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...